MedTrace Logo

Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects

NCT02681055 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2023-03-15

Study results available
· View outcomes & findings →

Summary

This is a multi-center, proof-of-principle, open-label study designed to evaluate the efficacy, safety, and tolerability of MN-001 in non-alcoholic steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) subjects with hypertriglyceridemia.

Conditions

  • Non-alcoholic Steatohepatitis
  • Hypertriglyceridemia
  • Non-alcoholic Fatty Liver Disease
  • Hypercholesterolemia

Interventions

DRUG

MN-001

MN-001 is a novel, orally bioavailable small molecule compound which demonstrates anti-inflammatory activity

Sponsors & Collaborators

  • MediciNova

    lead INDUSTRY

Principal Investigators

  • Kazuko Matsuda, MD PhD MPH · MediciNova

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2018-05-30
Completion
2019-10-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02681055 on ClinicalTrials.gov